Survival Analysis after i.a. 90Y-DOTATATE PRRT, in Patients with Non-Resectable, Advanced, Progressive, Liver-Dominant Neuroendocrine Neoplasms

#1894

Introduction: A

Aim(s): To assess long-term survival in non-resectable, progressive, liver-dominant GEP-NEN after intraarterial (i.a.) 90Y DOTATATE peptide receptor radionuclide therapy-PRRT

Materials and methods: 22 subjects, 12 female, mean age 56.2. Histological proven G1/G2/G3: 4/17/1; secretor 10 pts (46%). Documented progression DP: 100% (RECIST, clinical or biochemical in case or secretor tumors) with relapse on previous therapy. Overall 56 i.a. 90Y-DOTATATE sessions. Initial tumor responses assessed, 6wks after PRRT and then 3mo intervals of follow-up. Objective tumor response was classified according to RECIST 1.0, initially 6wks and then after each of the 6mo. OS and PFS were evaluated using Kaplan Meier methods

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Nowicki M, Kolasińska-Ćwikła A, Lewczuk A, Sankowski A, Bodei L,

Keywords: intra-arterial PRRT, progressive GEP-NENs, liver dominant,